IDH1 and central nervous system cancer: Consequently, the number of patients in each subgroup (e.g., multifocal lesions, IDH-mutant grade IV glioma, or IDH-wildtype grade II glioma) is limited, potentially reducing statistical power and increasing uncertainty in subgroup analyses.